Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by F. Morschhauser
A FDG-PET Driven Consolidation Strategy in Diffuse Large B-Cell Lymphoma: Final Results of a Randomized Phase II Study
Blood
Biochemistry
Immunology
Cell Biology
Hematology
A New Pharmacokinetic Model for 90y-Ibritumomab Tiuxetan Based on 3-Dimensional Dosimetry
Scientific Reports
Multidisciplinary
Development and Validation of an UHPLC-MS/MS Method for Simultaneous Quantification of Ibrutinib and Its Dihydrodiol-Metabolite in Human Cerebrospinal Fluid
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Biochemistry
Clinical Biochemistry
Analytical Chemistry
Cell Biology
Medicine
LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: A LYSA STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The 5-Year Follow-Up Results of the C5r Protocol With Rituximab and Intrathecal Liposomal Cytarabine for Primary CNS Lymphoma: A Prospective Phase 2 Study of the Lysa
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-Chop in Patients (Pts) With Untreated DLBCL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd20-TCB (Rg6026), a Novel “2:1” Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
1
2
›